BioCentury
ARTICLE | Clinical News

Sage jumps on Phase II data for MDD candidate

December 7, 2017 11:26 PM UTC

Sage Therapeutics Inc. (NASDAQ:SAGE) gained $64.37 (70%) to $156.27 on Thursday after reporting that SAGE-217 met the primary endpoint in a Phase II trial to treat moderate to severe major depressive disorder. Sage added over $2 billion to its market cap on the news.

On the 89-patient trial's primary endpoint, once-daily 30 mg oral SAGE-217 for 14 days significantly reduced mean Hamilton Rating Scale for Depression (HAM-D) total score from baseline to day 15 by 17.6 points vs. 10.7 points for placebo (p<0.0001). The company said SAGE-217 showed a significant improvement in HAM-D total score compared to placebo by day two (p<0.0318) and was maintained through week four -- two weeks after the end of treatment...